ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1936

A De Novo Dominant-negative PSMB8 mutation is Linked to a More Severe CANDLE-like Phenotype

Sara Alehashemi1, Adriana Almeida de Jesus2, Jonas Johannes Papendorf3, Farzana Bhuyan4, Kat Uss5, Anvitha Metpally6, Bin Lin7, Sophia Park8, Thais C.L. Moura9, Renata R Dias9, Mayra B. Dorna9, Katia Kozu9, Adriana Sallum9, Lucia M. A. Campos9, Gijs Santen10, Jesper Kers10, Onno Teng11, Karin Palmblad12, Tom Huizinga10, Frédéric Ebstein13, Elke Krüger13 and Raphaela Goldbach-Mansky14, 1NIH/NIAID/TADS, Clarksville, MD, 2NIAID, NIH, Silver Spring, MD, 3Institut für Medizinische Biochemie und Molekularbiologie, Universitätsmedizin Greifswald, Greifswald, Germany, 4National Institutes of Health, Bethesda, MD, 5National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 6NIAID, NIH, Bethesda, MD, 7NIH, Bethesda, MD, 8NIAID, Bethesda, MD, 9Children's Hospital of the University of São Paulo, São Paulo, Brazil, 10Leiden University Medical Center, Leiden, Netherlands, 11Leiden University Medical Center, Leiderdorp, Netherlands, 12Karolinska University Hospital, Stockholm, Sweden, 13Institut für Medizinische Biochemie und Molekularbiologie (IMBM), Universitätsmedizin Greifswald, Greifswald, Germany, 14NIH/NIAID, Potomac, MD

Meeting: ACR Convergence 2022

Keywords: Autoinflammatory diseases, genetics, immunology, innate immunity, interferon

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Pediatric Rheumatology – Clinical Poster III: Other

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Homozygote (HM)/compound heterozygote (CH) and digenic (DG) mutations in proteasome subunits cause the autoinflammatory syndrome CANDLE, or proteasome-associated autoinflammatory syndrome (PRAAS). Inflammation is mediated by type I interferon (IFN I) due to proteotoxic distress, partially through protein kinase R (PKR) activation1. Patients (pts) with heterozygous (HZ) loss of function PSMB9 mutations are described2. We report five pts with heterozygote PSMB8 mutations and severe disease.

Methods: Pts with elevated IFN scores or clinical features of an interferonopathy were enrolled in an IRB-approved natural history protocol. We characterized clinical and immunological phenotype, measured IFN I score and performed targeted genetic analysis. We studied monocytes in culture and assessed the mutation’s effect on proteosome in HeLa cells and patients’ T cell blasts.

Results: All had heterozygotes PSMB8 mutations p.Gly209Arg due to base pair change c.635G >A (n=4), or c.635G >C (n=1). Clinical features are listed in the Table. All had perinatal onset of CANDLE-like symptoms, fevers, neutrophilic panniculitis, myositis, systemic inflammation and elevated IFN I score. Other features include lymphopenia, hypogammaglobulinemia, chronic infections, portal hypertension, colitis and proteinuria that are rare or absent in HZ or CH PSMB8. All required high-dose steroids. One died at 25 from variceal bleed. Treatment with JAK inhibitors, baricitinib (n=2), and tofacitinib (n=2) improved systemic inflammation and allowed tapering of the steroids. However, cytopenia (n=5) and recurrent infections are ongoing (n= 4). One has persistent lung aspergillosis, two had pseudomonas lung infections, one had PJP and one has persistent EBV viremia and norovirus/sapovirus in the stool. All are on replacement immunoglobulins. Functional assays showed that intracellular protein aggregates were increased consistent with severe proteasome dysfunction. The pts’ monocyte-derived macrophages produce high IL-8, IL-6 upon stimulation like other CANDLE pts compared to controls. In vitro, mutation cause a dominant negative effect with accumulation of proteasome precursors that do not mature. It inhibits compensatory POMP/Beta5 expressions, and disrupts proteosome assembly and maturation in HeLa cells, in a dominant-negative way. In vitro treatment of the T cells with PKR inhibitor and JAKinhibitor decreased Interferon-Stimulated Genes transcription.

Conclusion: We describe 5 pts with HZ dominant negative PSMB8 mutations who expand the spectrum of CANDLE. Like HZ PSMB9 mutations and DN POMP mutations, they have infections suggestive of T cell dysfunction and respond partially to JAKinhibitors. Our report points to the need to evaluate the effect of novel mutations on proteasome functions in patients presenting with neutrophilic rashes and CANDL like presentations. 

1Kanazawa, et al. “HZ missense variant of the proteasome subunit β-type 9 causes neonatal-onset autoinflammation and immunodeficiency.” Nature commun. 2021

2 Davidson, et al. PKR is an innate immune sensor of proteotoxic stress via accumulation of cytoplasmic IL-24. Science Immun. 2022

Acknowledgments: This work was supported by DIR at NIAID/NIH.

Supporting image 1

Clinical characteristics of patients with dominant negative PSMB8 p.Gly209Arg mutation

Supporting image 2

Clinical characteristics of patients with dominant negative PSMB8 p.Gly209Arg mutation

Supporting image 3

Clinical characteristics of patients with dominant negative PSMB8 p.Gly209Arg mutation


Disclosures: S. Alehashemi, None; A. Almeida de Jesus, None; J. Papendorf, None; F. Bhuyan, None; K. Uss, None; A. Metpally, None; B. Lin, None; S. Park, None; T. Moura, None; R. Dias, None; M. Dorna, None; K. Kozu, None; A. Sallum, None; L. Campos, None; G. Santen, None; J. Kers, None; O. Teng, GlaxoSmithKlein(GSK), Kezar, Aurinia Pharamceuticals, Novartis; K. Palmblad, None; T. Huizinga, None; F. Ebstein, None; E. Krüger, None; R. Goldbach-Mansky, None.

To cite this abstract in AMA style:

Alehashemi S, Almeida de Jesus A, Papendorf J, Bhuyan F, Uss K, Metpally A, Lin B, Park S, Moura T, Dias R, Dorna M, Kozu K, Sallum A, Campos L, Santen G, Kers J, Teng O, Palmblad K, Huizinga T, Ebstein F, Krüger E, Goldbach-Mansky R. A De Novo Dominant-negative PSMB8 mutation is Linked to a More Severe CANDLE-like Phenotype [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/a-de-novo-dominant-negative-psmb8-mutation-is-linked-to-a-more-severe-candle-like-phenotype/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-de-novo-dominant-negative-psmb8-mutation-is-linked-to-a-more-severe-candle-like-phenotype/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology